Source: Eur Respir J, 57 (6) 2100166; 10.1183/13993003.00166-2021



Rating:

Share or cite this content

Citations should be made in the following way:
Andrew P. Hearn, Oliver D. Hug, Ziana A. Somani, Joanne Kavanagh, Grainne d'Ancona, Cris Roxas, Linda Green, Louise Thomson, Mariana Fernandes, Brian D. Kent, Jaideep Dhariwal, Alexandra M. Nanzer, David J. Jackson. Real world effectiveness of anti-IL-5/5R therapies is independent of co-eligibility for anti-IgE therapy. Eur Respir J, 57 (6) 2100166; 10.1183/13993003.00166-2021

Member's Comments

No comment yet.

Related content which might interest you: Comparative efficacy of the therapy strategies for the asthma control maintenance in real clinical practice Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Combination therapy in the era of immunotherapy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006 Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Source: Eur Respir J 2001; 18: Suppl. 33, 24s Year: 2001 Valuing the real world benefits of omalizumab Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 Real world effectiveness of changing combination therapy in primary care asthma management Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 When omalizumab is effective, should treatment be for life? Source: International Congress 2018 – Asthma management Year: 2018 Real world use of opioids in COPD patients Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care Year: 2020 The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD Source: Eur Respir J 2001; 18: Suppl. 33, 5s Year: 2001 Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021 Evaluating response to omalizumab (anti-IgE) in clinical practice Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Efficacy and safety of Mepolizumab in a real world severe asthma cohort. Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real life application of basophil activation test: A real challenge for diagnosis and treatment monitoring of atopy-related diseases? Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Cost-effectiveness of fixed-dose combinations therapies for COPD in Spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 The real world effectiveness and effect on adherence with inhaled asthma therapy of 1 year of Severe Asthma Monoclonal Antibody Treatment Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020